Literature DB >> 28279417

Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction.

Kirsten Rose-Felker1, William L Border2, Borah J Hong3, Eric J Chow4.   

Abstract

Although tremendous advances in pediatric cancer treatment have improved the survival of many children, these patients remain at increased risk of early morbidity and mortality with cardiovascular disease as a leading cause of death. Heightened awareness in providers with increased surveillance and improvement in cardiovascular imaging modalities have led to earlier detection of cardiac dysfunction, but the outcomes remain poor once this has dysfunction developed. A great deal of work remains to be done to refine screening and identify high-risk patients more precisely, and to develop more evidence-based strategies for effective primary and secondary cardioprotection and treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anthracyclines; Cardiac dysfunction; Cardiotoxicity; Childhood cancer survivors

Mesh:

Substances:

Year:  2017        PMID: 28279417     DOI: 10.1016/j.hfc.2016.12.007

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  7 in total

Review 1.  The Association of New-Onset Atrial Fibrillation and Risk of Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mengxia Zhang; Lin-Ling Li; Qian-Qian Zhao; Xiao-Dong Peng; Kui Wu; Xin Li; Yan-Fei Ruan; Rong Bai; Nian Liu; Chang Sheng Ma
Journal:  Cardiol Res Pract       Date:  2020-09-27       Impact factor: 1.866

2.  Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice.

Authors:  Ibrahim Y Abdelgawad; Marianne K O Grant; Flavia E Popescu; David A Largaespada; Beshay N Zordoky
Journal:  Int J Mol Sci       Date:  2021-08-21       Impact factor: 5.923

3.  Challenges associated with retrospective analysis of left ventricular function using clinical echocardiograms from a multicenter research study.

Authors:  Ritu Sachdeva; Kayla L Stratton; David E Cox; Saro H Armenian; Aarti Bhat; William L Border; Kasey J Leger; Wendy M Leisenring; Lillian R Meacham; Karim T Sadak; Shanti Narasimhan; Eric J Chow; Paul C Nathan
Journal:  Echocardiography       Date:  2021-01-24       Impact factor: 1.724

Review 4.  Pharmacogenetics implementation in the clinics: information and guidelines for germline variants.

Authors:  Gladys Olivera; Luis Sendra; María José Herrero; Pablo Berlanga; Pablo Gargallo; Yania Yáñez; Andrea Urtasun; Jaime Font de Mora; Victoria Castel; Adela Cañete; Salvador F Aliño
Journal:  Cancer Drug Resist       Date:  2019-03-19

Review 5.  Acquired and modifiable cardiovascular risk factors in patients treated for cancer.

Authors:  Gary S Beasley; Jeffrey A Towbin
Journal:  J Thromb Thrombolysis       Date:  2020-09-12       Impact factor: 2.300

6.  Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.

Authors:  Kelly D Getz; Lillian Sung; Bonnie Ky; Robert B Gerbing; Kasey J Leger; Allison Barz Leahy; Leah Sack; William G Woods; Todd Alonzo; Alan Gamis; Richard Aplenc
Journal:  J Clin Oncol       Date:  2018-10-31       Impact factor: 50.717

Review 7.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.